Sentence examples for this trial will demonstrate from inspiring English sources

This trial will demonstrate whether IAH can be reversed and SH prevented in people with T1DM in even those at highest risk by using optimized conventional management and existing technology.

It is anticipated that this trial will demonstrate the scalability of MHFA in the university environment for pre-service nurses and that implementation of MHFA courses, with comprehensive evaluation, could yield positive improvements in the mental health literacy amongst this target group as well as other tertiary student groups.

The results of this trial will demonstrate whether or not the use of hr-HPV testing as a single primary screening test within a population based cervical cancer screening program will be able to provide further reductions in the incidence of cervical cancer and its precursor lesions, allow the screening interval to be extended, and improve the cost-effectiveness of cervical cancer screening.

Fikret Grabovica, who heads the association of parents of children killed in the siege of Sarajevo, said: "It's important he be sentenced, so that everyone knows what really happened here... I hope that many of those who have illusions and believe that Mladic is a Serb hero will change their minds and that the trial will demonstrate he was just a criminal and a coward".

We hope the trial will demonstrate feasibility of a pragmatic randomised trial of BITES and help quantify therapeutic effect.

If the a/b ratio for prostate cancer is closer to 10, the trial will demonstrate equivalence between the fractionation regimens; if it is closer to 1.5, the HFRT schedule should produce better rates of biochemical control.

Based on the success that has been achieved with supported online treatments for depression [ 34] we hypothesize that participants in the trial will demonstrate significant decreases in depressive symptoms post-intervention and a corresponding increase in quality of life indicators.

This ambitious and intensive trial will demonstrate definitively whether SH, a cause of major morbidity in up to 5000 adults with T1DM in the UK, can be prevented successfully in even those at highest risk by optimised conventional management using existing technology.

The available data suggest that these trials will demonstrate significant improvements, thus helping to convince health authorities that geriatric oncology teams must receive strong support.

Based on our recent experimental findings with complex modeling of acute stroke care (Susann Hetze, Odilo Engel, Christine Roemer, Susanne Mueller, Christian Meisel and A.M., unpublished data), we speculate that the PASS trial will demonstrate that preventive anti-infective treatment improves neurological outcome but not survival.

The hope is that ongoing phase 3 clinical trials will demonstrate similar efficacy and safety profiles for denosumab therapy in PMO and metastatic cancer.